Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
Citação
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, v.22, n.1, p.63-72, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Adjuvant chemotherapy with trastuzumab for HER2 positive breast cancers has brought considerable benefits to disease-free survival and overall survival. Objective: To conduct a cost-effectiveness analysis of the treatment of patients with early and locally advanced HER2 positive breast cancer, within the scope of the Brazilian public health system, comparing adjuvant chemotherapy with and without trastuzumab, for 1 year of treatment. Methods: A 4-state Markov model was developed to estimate strategy costs and outcomes. Results: Based on the proposed model, we verified an incremental benefit of trastuzumab therapy compared to treatment without trastuzumab with 0.84 quality-adjusted life years (QALY) and 1.16 life years gained (LYG). The use of adjuvant chemotherapy with trastuzumab has an ICER of US$19,599.26 for each quality-adjusted life year and US$14,180.68 for each life year gained in relation to chemotherapy without trastuzumab. Conclusion: In Brazil, adjuvant chemotherapy with trastuzumab may be considered cost-effective only if a cost-effectiveness threshold is stipulated with the value starting at three times the Brazilian GDP per capita for QALY or two times the Brazilian GDP per capita for LYG, from health system perspective.
Palavras-chave
Key-words, Health Economics, economic Evaluation, cost-effectiveness, cost-utility, health System, HER2 Positive Breast Cancer
URI
https://observatorio.fm.usp.br/handle/OPI/44646
Referências
  1. Aboutorabi Ali, 2014, Glob J Health Sci, V7, P98, DOI 10.5539/gjhs.v7n1p98
  2. [Anonymous], 2018, CLIN PROTOCOLS THERA
  3. Ansaripour A, 2018, PHARMACOECONOMICS, V36, P91, DOI 10.1007/s40273-017-0557-6
  4. Buendia JA, 2013, BIOMEDICA, V33, P411, DOI 10.7705/biomedica.v33i3.832
  5. Barros AJD, 2008, INT J EPIDEMIOL, V37, P758, DOI 10.1093/ije/dyn063
  6. Brazilian Institute of Geography and Statistics, 2017, COMPL MORT TABL 2017
  7. Briggs A, 2006, DECISION MODELLING H
  8. Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2
  9. Cooper, 2012, EVIDENCE SYNTHESIS D, P293
  10. Diaby V, 2015, BREAST CANCER RES TR, V151, P27, DOI 10.1007/s10549-015-3383-6
  11. Ferrusi IL, 2009, PERS MED, V6, P193, DOI 10.2217/17410541.6.2.193
  12. Genuino AJ, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4715-8
  13. Gobetti, 2018, TRIBUTACAO CAPITAL B
  14. GOBETTI SÉRGIO WULFF, 2017, Brazil. J. Polit. Econ., V37, P267, DOI 10.1590/0101-31572017v37n02a01
  15. Hajjar A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217778
  16. Hall PS, 2011, PHARMACOECONOMICS, V29, P415, DOI 10.2165/11588340-000000000-00000
  17. Hoff PMG., 2018, MANUAL CONDUCT ONCOL, P276
  18. Hulme, 2015, COST EFFECTIVENESS M, P217
  19. [IARC] International Agency for Research on Cancer, 2020, LAT GLOB CANC DAT CA
  20. Ioannou SS, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124339
  21. Krehbiel, 2017, STAT MANAGERS USING, P800
  22. Lang HC, 2016, J MED ECON, V19, P923, DOI 10.1080/13696998.2016.1185013
  23. Leung W, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002067
  24. Macedo A, 2010, ACTA MEDICA PORT, V23, P475
  25. Massuda A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000829
  26. Methodological guidelines: Economic evaluation guideline, 2014, METH GUID EC EV GUID, P134
  27. Millar JA, 2007, PHARMACOECONOMICS, V25, P429, DOI 10.2165/00019053-200725050-00006
  28. Ministry of Health, 2017, CANC INC BRAZ
  29. Moja L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006243.pub2
  30. Orair RO., 2016, PROGRESSIVIDADE TRIB
  31. Petrou P, 2019, EXPERT REV PHARM OUT, V19, P115, DOI 10.1080/14737167.2019.1536549
  32. Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
  33. Rascati KL., 2009, ESSENTIALS PHARMACOE
  34. Saad ED, 2019, LANCET ONCOL, V20, P361, DOI 10.1016/S1470-2045(18)30750-2
  35. Santos IS, 2018, CIENC SAUDE COLETIVA, V23, P2303, DOI 10.1590/1413-81232018237.09192018
  36. Seferina SC, 2017, ONCOTARGET, V8, P79223, DOI 10.18632/oncotarget.16985
  37. Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383
  38. Walter E., 2019, REGULATORY EC ASPECT
  39. Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
  40. World Health Organization, 2020, TOP 10 CAUS DEATH

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03